Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $1.8 million.

  • 10x Genomics' Capital Expenditures fell 3457.29% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.9 million, marking a year-over-year decrease of 5211.01%. This contributed to the annual value of $5.9 million for FY2025, which is 5211.01% down from last year.
  • As of Q4 2025, 10x Genomics' Capital Expenditures stood at $1.8 million, which was down 3457.29% from $687000.0 recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Capital Expenditures peaked at $39.7 million during Q4 2022, and registered a low of -$753000.0 during Q2 2023.
  • Over the past 5 years, 10x Genomics' median Capital Expenditures value was $9.2 million (recorded in 2021), while the average stood at $15.0 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 387387.03% in 2021, then tumbled by 10276.64% in 2023.
  • Quarter analysis of 5 years shows 10x Genomics' Capital Expenditures stood at $27.6 million in 2021, then skyrocketed by 43.87% to $39.7 million in 2022, then crashed by 91.32% to $3.4 million in 2023, then dropped by 21.28% to $2.7 million in 2024, then plummeted by 34.57% to $1.8 million in 2025.
  • Its Capital Expenditures stands at $1.8 million for Q4 2025, versus $687000.0 for Q3 2025 and $1.6 million for Q2 2025.